A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market
A Competitive Analysis of the Global Acute Coronary Syndrome (ACS) Therapeutics Market
Launch of Promising Late-stage Anti-hypertensive Drugs to Drive Growth of Branded ACS Therapeutics
RELEASE DATE
20-May-2015
20-May-2015
REGION
Global
Global
Research Code: MB06-01-00-00-00
SKU: LS00109-GL-MR_16950
$3,950.00
In stock
SKU
LS00109-GL-MR_16950
Description
This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are broadly segmented into anti-platelet therapeutics, anti-hypertensives and cholesterol lowering drugs, anti-thrombins, and others. Other upcoming therapies include anti-inflammatories. The forecast period is 2015–2025.
Table of Contents
Executive Summary—Key Findings
Executive Summary—Key Findings (continued)
Key Trends
Companies to Watch
Methodology and Scope
Market Overview—Introduction
Market Overview—Epidemiology
Market Overview—Epidemiology (continued)
Market Overview—Epidemiology (continued)
Physicians Treatment Guidelines
Physicians Treatment Guidelines (continued)
Physicians Treatment Guidelines (continued)
Physicians Treatment Guidelines (continued)
Market Size
Market Size—Segmentation
Market Forecast
Market Segmentation
Competitive Landscape Overview
Competitive Landscape—Marketed and Pipeline Products
Marketed Products—Anti-platelet Therapy
Pipeline Products—Anti-platelet Therapy
Marketed Products—Anti-thrombin Therapy
Marketed Products—Anti-thrombin Therapy (continued)
Pipeline Products—Anti-thrombin Therapy
Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs
Marketed Products—Anti-hypertensives & Cholesterol Lowering Drugs (continued)
Pipeline Products—Anti-hypertensives & Cholesterol Lowering Drugs
Pipeline Products—Others
Product Launch Timeline
Patent Expirations
ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials
ACS Therapeutics—Major Ongoing/Recently Completed Clinical Trials (continued)
Summary of Key Products to Watch
Product Dashboard: Plavix (clopidogrel)—Bristol-Myers Squibb
Product Dashboard: Brilinta (ticagrelor)—The Medicines Company
Product Dashboard: Angiomax—The Medicines Company
Product Dashboard: Zocor (simvastatin)—Merck
Product Dashboard: Xarelto (rivaroxaban)—Bayer
Product Dashboard: Alirocumab (RGN727)—Sanofi & Regeneron
Product Dashboard: Evolocumab (Repatha)—Amgen
Product Dashboard: Evacetrapib—Eli Lilly & Company
Product Dashboard: Losmapimod—GSK
Conclusions
Legal Disclaimer
Decision Support Database
Decision Support Database (continued)
Decision Support Database (continued)
Decision Support Database (continued)
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Related Research
China is predicted to become the third-largest pharmaceutical market in the world by the end of 2013 due to the governments considerable investment in the healthcare industry and the populations unmet healthcare needs. The life sciences industry is broad and involves a wide range of disciplines. This research service focuses on the trends and market opportunities in Chinas life sciences industrythe regulatory environment, the registration pathway of various drugs and IVD products, and M&A. Medical devices and the related registration pathway are not included. In this study, the base year is 2012, and the forecast period runs 20132017. An analysis of market challenges, drivers, and restraints impacting industry growth are provided.
No Index | No |
---|---|
Podcast | No |
Author | Sriram Radhakrishnan |
WIP Number | MB06-01-00-00-00 |
Is Prebook | No |